ATRA NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Atara Biotherapeutics Inc · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 7.90 USD
-5.8% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 3.9% above the Trend Line and sits at 26.1% of its 52-week range. The latest completed week returned -5.8%, after a -24.8% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 45/100. Near-term considerations: volume confirmation is below normal; earnings are due in 12d.

Setup score 28 out of 100
Latest Close 7.90 USD 24 Jul 2026
1W Return -5.8% latest completed week
4W Return -24.8% short-term follow-through
12W Return 61.2% quarterly tape
Trend Breadth 50.0% 26 of 52 weeks active
Volume Ratio 0.0x vs 13-week average
What is working
  • The trend backdrop is active with a 2-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • The share remains more than 20% below its 52-week high.
  • The latest week was a sharp negative move.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -5.8% Latest completed week; four-week move -24.8%. Indicator stack 34/55 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 45/100 64 relevant articles in the latest sentiment read. Event risk 12d Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 3.9% above the Trend Line and sits at 26.1% of its 52-week range. The latest completed week returned -5.8%, after a -24.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.0x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.4912-week average 0.27

12-week confirmation

Trend active2/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.49Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -24.8% over four weeks, 61.2% over 12 weeks, and -31.8% over one year. The current trend has remained active for 2 consecutive weeks.

Performance by holding period

1W-5.8%
4W-24.8%
12W61.2%
26W51.3%
52W-31.8%
Active trend streak2 weeks
Active weeks in one year26
Trend breadth50.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.46Latest activity-pressure read.
Pressure change-42.2%Four-week change in activity pressure.
Leadership-29.68Latest relative-leadership reading.
RS change-165.9%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 73% Model confidence 70%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength72/100Blend of value, momentum, and quality. Underlying universe rank 29; rank 1 is best.
Value60/100Relative valuation strength. Underlying universe rank 41; rank 1 is best.
Quality59/100Profitability and accounting quality. Underlying universe rank 42; rank 1 is best.
Momentum61/100Medium-term price momentum. Underlying universe rank 40; rank 1 is best.
Growth61/100Revenue and earnings growth. Underlying universe rank 40; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
3.1x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-35.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
96.1%
Gross profit retained from each unit of revenue.
Operating margin
-25.2%
Operating profit retained from revenue.
Free-cash-flow margin
-111.8%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-88.4%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-22.9%
Net share repurchases relative to market value.
Shareholder yield
-22.9%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity6 / 7

6 acquisitions and 7 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment45/100

Weighted news tone is neutral across 64 relevant articles.

6 positive · 43 neutral · 15 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings12dNext report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-58.7%Distance below the 52-week high.
13-week volatility20.7%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+70.2%Week of 8 May.
Worst week-24.5%Week of 20 Mar.
Latest week-5.8%Week of 24 Jul.

Shape of recent returns

Strong gains10
Modest gains1
Flat weeks0
Modest losses3
Sharp losses12
Recent vol20.7%13-week weekly-return volatility.
Base vol17.4%52-week weekly-return volatility.
Up/down split24/28Count of positive and negative weeks in the 52-week window.
Average skew12.8% / -9.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape27/100

Trend, activity pressure, participation, and risk combine to a 27/100 tape read.

 Indicator analysis43/100

Latest 12-week confirmation: trend 2/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.49; No reversal markers Factors62/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 92; Small Cap Core rank 48 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment45/100

Weighted news tone is neutral across 64 relevant articles.

Atara Biotherapeutics Inc (ATRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution Insiders6 / 7

6 acquisitions and 7 disposals in the latest 180-day insider tape.

 Earnings12d

Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20267.90 USD-5.8%7.61 USD13.58 USD0.46-29.68258.3KOn
17 Jul 20268.39 USD-14.0%7.92 USD13.86 USD0.71-27.27534.5KOn
10 Jul 20269.76 USD-16.2%8.21 USD14.15 USD0.84-19.46452.7KOff
3 Jul 202611.65 USD10.8%8.48 USD14.38 USD0.89-2.49235.5KOff
26 Jun 202610.51 USD4.4%8.57 USD14.60 USD0.80-11.16362.9KOff
19 Jun 202610.07 USD-3.3%8.73 USD14.79 USD0.80-18.68473.8KOff
12 Jun 202610.41 USD4.9%8.85 USD15.01 USD0.83-13.84374.3KOff
5 Jun 20269.92 USD-5.6%8.96 USD15.26 USD0.84-16.23420.9KOff
29 May 202610.51 USD7.2%9.02 USD15.51 USD0.93-15.57595.7KOff
22 May 20269.80 USD2.3%9.17 USD15.69 USD0.74-19.08927.1KOff
15 May 20269.58 USD14.9%9.32 USD15.92 USD0.58-19.973.1MOff
8 May 20268.34 USD70.2%9.50 USD16.19 USD0.27-30.5379.4MOff
1 May 20264.90 USD-2.2%9.70 USD16.48 USD-0.27-57.10246.2KOff
24 Apr 20265.01 USD-4.9%10.01 USD16.92 USD-0.57-55.89239.3KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.